Johnson & Johnson/$JNJ
1D1W1MYTD1Y5YMAX
Capital at risk
About Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
- Ticker
- $JNJ
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 138,200
- Headquarters
- New Brunswick, United States
- Website
- www.jnj.com
JNJ Metrics
BasicAdvanced
$654B
31.44
$8.63
0.23
$5.28
1.98%
Price and volume
Market cap
$654B
Beta
0.23
52-week high
$281.07
52-week low
$177.32
Average daily volume
6.3M
Dividend rate
$5.28
Financial strength
Current ratio
1.089
Quick ratio
0.725
Long term debt to equity
0.439
Total debt to equity
0.677
Dividend payout ratio (TTM)
59.99%
Interest coverage (TTM)
26.80%
Profitability
EBITDA (TTM)
34,872
Gross margin (TTM)
68.10%
Net profit margin (TTM)
21.48%
Operating margin (TTM)
27.62%
Effective tax rate (TTM)
16.51%
Revenue per employee (TTM)
$710,000
Management effectiveness
Return on assets (TTM)
8.59%
Return on equity (TTM)
25.74%
Valuation
Price to earnings (TTM)
31.439
Price to revenue (TTM)
6.669
Price to book
7.69
Price to tangible book (TTM)
-39.72
Price to free cash flow (TTM)
29.879
Free cash flow yield (TTM)
3.35%
Free cash flow per share (TTM)
9.077
Dividend yield (TTM)
1.95%
Forward dividend yield
1.98%
Growth
Revenue change (TTM)
8.06%
Earnings per share change (TTM)
-7.68%
3-year revenue growth (CAGR)
5.95%
10-year revenue growth (CAGR)
3.29%
3-year earnings per share growth (CAGR)
20.48%
10-year earnings per share growth (CAGR)
4.86%
3-year dividend per share growth (CAGR)
4.59%
10-year dividend per share growth (CAGR)
5.56%
What the Analysts think about JNJ
Analyst ratings (Buy, Hold, Sell) for Johnson & Johnson stock.
Analyst projections of the future price of Johnson & Johnson stock.
Bulls say / Bears say
J&J is showing resilience through the STELARA patent loss: second-quarter sales rose 6.6% and management raised its 2026 outlook to $101.1 billion of revenue and $11.68 of adjusted EPS at the mid-point. (Johnson & Johnson)
The oncology franchise has room to expand beyond its existing blockbusters. FDA approval of TECVAYLI with DARZALEX FASPRO in earlier-line multiple myeloma, plus strong follow-up survival data, could widen the addressable market for two key therapies. (Johnson & Johnson, Johnson & Johnson)
MedTech is gaining new product catalysts rather than relying solely on mature devices. J&J reports growth in electrophysiology, surgery and cardiovascular products, alongside FDA authorisation for its dual-energy ablation platform and progress on the OTTAVA surgical robot. (Johnson & Johnson, Stock Analysis)
STELARA remains a major earnings headwind: biosimilar competition reduced Innovative Medicine growth by about 760 basis points in the second quarter. Further competition for SIMPONI and OPSUMIT could extend the pressure into the rest of 2026. (Johnson & Johnson, Yahoo Finance)
MedTech is the weaker growth engine at present: second-quarter operational growth was 3.6%, well below Innovative Medicine’s 6.8%. A slower device business leaves less room to absorb further pharmaceutical patent erosion. (Johnson & Johnson, StockTitan)
The proposed talc resolution would commit J&J to $5.5 billion, with up to $3 billion due in 2027, yet it still depends on participation by firms representing at least 95% of remaining claims. Until that condition is met, the company faces both a large cash outflow and continued legal uncertainty. (Johnson & Johnson, Asbestos.com)
Data summarised monthly by Lightyear AI. Last updated on 25 Sept 2026.
JNJ Financial Performance
Revenues and expenses
JNJ Earnings Performance
Company profitability
Upcoming events
No upcoming events
JNJ News
AllArticlesVideos
Funds containing JNJ
AllEURUSDGBP
Fund name | Fund size | $JNJ weighting |
|---|---|---|
iShares S&P 500 Health Care Sector€IUHE | €125M | 10.57% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 6.27% |
iShares MSCI USA Islamic$ISDU | $594M | 3.76% |
iShares MSCI USA Islamic£ISUS | £438M | 3.76% |
iShares Dow Jones Industrial Average€EXI3 | €315M | 3.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.